A phase III trial of adjuvant Prolia (denosumab) therapy in postmenopausal women with early hormone receptor positive breast cancer receiving aromatase inhibitor therapy met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001).
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
